In this study, we report our observations that introduction of the most frequent hotspot mutation in SF3B1 gene in K562 cells results in an increased frequency of polyploid multinucleated giant cells that are resistant to serum starvation conditions and commonly used chemotherapeutic agent, azacytidine, approved for the treatment of both MDS and AML. This evidence concerns the gene SF3B1 and acute myeloid leukemia.